ALASKA AIR GROUP INC
ALKNYSETrading Snapshot
- Day Range
- $35.26 – $36.06
- 52-Week Range
- $32.33 – $60.63
- Volume (shares)
- 3,208,934
- Avg Volume (shares)
- —
- Shares Outstanding
- 111.6M
- Next Earnings
- 2027-01-28
Fundamentals Snapshot
- Annual Revenue
- $14.24B
- Last Q Revenue
- $4.31B
- P/E Ratio
- -10.1
- P/S Ratio
- 0.3x
- EPS (TTM)
- $-3.54
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −9.0%
ALASKA AIR GROUP INC
ALK
StockOtter · stockotter.spaceAbout ALASKA AIR GROUP INC
Alaska Air Group, Inc. operates via its subsidiaries, providing comprehensive air transportation solutions for both passengers and freight. Its business is organized into three principal segments: Mainline, Regional, and Horizon. The airline extends its services to approximately 120 destinations throughout North America. Originally established in Seattle, Washington, in 1932, the company maintains its corporate base in that city.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
Should Investors Avoid Alaska Air Stock Despite Q3 Earnings Beat?
We assess the investment worthiness of ALK stock post its third-quarter 2026 earnings release.
Alaska Airlines to launch nonstop service between Anchorage and Tokyo Narita
/PRNewswire/ -- Alaska Airlines will launch its first nonstop service between Anchorage and Tokyo Narita* next spring, creating a convenient new connection
Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer
Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial
Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
US airlines favor higher fares over fuller planes as fuel costs squeeze profits
US airlines favor higher fares over fuller planes as fuel costs squeeze profits
Alaska Air Group Q3 Earnings Call Highlights
Alaska Air Group (NYSE: ALK) reported a third-quarter GAAP net loss of $147 million, or $1.32 per share, as elevated fuel costs weighed on profitability despite higher revenue and improving unit-revenue trends. Excluding